8-K: Akari Therapeutics Faces Nasdaq Delisting Warning

Akari Therapeutics received a Nasdaq notification for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Summary

• Akari Therapeutics, Plc (AKTX) was notified by Nasdaq Listing Qualifications on November 24, 2025, that it is not in compliance with Nasdaq Listing Rule 5550(a)(2).
• The rule requires listed securities to maintain a minimum bid price of $1.00 per share.
• The deficiency arose because the closing bid price of the company's American Depositary Shares (ADSs) was below $1.00 for 30 consecutive business days prior to the notification date.
• Each ADS represents 2,000 ordinary shares of the company.
• The notification has no immediate effect on the listing or trading of the ADSs, which will continue to trade on The Nasdaq Capital Market under the symbol AKTX.
• The company has 180 calendar days, until May 25, 2026, to regain compliance.
• To regain compliance, the ADSs must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• If compliance is not met by May 25, 2026, the company may be eligible for an additional 180-day period if it meets other listing requirements and provides notice of intent to cure.
• Failure to regain compliance could lead to delisting, with an opportunity to appeal to a Hearings Panel.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the formal notification of non-compliance with Nasdaq's minimum bid price requirement, which carries a significant risk of delisting. While there's a compliance period, the underlying issue of sustained low share price is a major concern for investors.

Positives

• The Nasdaq notification has no immediate effect on the listing or trading of Akari Therapeutics' ADSs.
• The company has a 180-calendar-day period, until May 25, 2026, to regain compliance with the minimum bid price requirement.
• There is a potential for an additional 180-day compliance period if certain conditions are met.

Negatives

• Akari Therapeutics is not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company's ADSs traded below $1.00 for 30 consecutive business days, indicating sustained low market valuation.
• Failure to regain compliance within the specified periods could result in the delisting of the company's ADSs from The Nasdaq Capital Market.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the minimum bid price requirement.
• Potential for reduced liquidity and investor interest if ADSs are delisted.
• Reputational damage associated with non-compliance and potential delisting.
• The need to implement corporate actions, such as an ADS ratio change, which could have further implications for shareholders.

Future Outlook

Akari Therapeutics intends to monitor the closing bid price of its ADSs and may consider implementing available options, including a ratio change of its ADSs, to regain compliance with Nasdaq's minimum bid price requirement.

Management Comments

• The company intends to monitor the closing bid price of its ADSs.
• The company may, if appropriate, consider implementing available options, including, but not limited to, implementing a ratio change of its ADSs, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

Industry Context

For a biotechnology company like Akari Therapeutics, maintaining a Nasdaq listing is crucial for access to capital, investor visibility, and perceived credibility. A delisting notice, even with a compliance period, signals underlying challenges, potentially related to clinical progress, financial health, or market sentiment, which can deter institutional investors and impact future fundraising efforts. Such notices are not uncommon for smaller biotech firms, but they highlight the intense scrutiny and capital market pressures within the sector.

Stakeholder Impact

• Shareholders: Face potential loss of liquidity and value if ADSs are delisted, and uncertainty regarding future corporate actions to regain compliance.
• Investors: May view the company as higher risk due to delisting threat, potentially impacting investment decisions.
• Employees: Could face uncertainty regarding the company's long-term stability and market presence.

Next Steps

• Monitor the closing bid price of the ADSs.
• Consider implementing available options, such as an ADS ratio change, to regain compliance.
• If compliance is not met by May 25, 2026, assess eligibility for a second 180-day compliance period and provide written notice of intent to cure.

Key Dates

Recommendation

The Nasdaq delisting notice for failing to meet the minimum bid price requirement signals significant underlying issues with the company's valuation and market perception. While there's a compliance period, the sustained low share price indicates a lack of investor confidence. The risk of delisting, even with potential remedies like an ADS ratio change, introduces substantial uncertainty and potential for further share price depreciation. Investors should consider selling to mitigate exposure to this heightened risk.

Keywords

Nasdaq, delisting, minimum bid price, compliance, AKTX, American Depositary Shares, biotechnology, stock market, regulatory notice